The STEP 1 trial showed semaglutide 2.4 mg led to 14.9% weight loss over 68 weeks, while SURMOUNT-1 showed tirzepatide achieved up to 20.9% weight reductionapproaching bariatric surgery outcomes.[6] The SELECT trial (17,604 patients) found semaglutide reduced cardiovascular death, non-fatal heart attack, and non-fatal stroke by 20% and all-cause mortality by 19%, suggesting direct cardioprotective effects beyond weight loss.[4] In STEP-HFpEF, semaglutide produced 13.3% weight loss in heart failure patients and improved symptoms and physical function
Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome
In most cases, its best to avoid alcohol for at least a few days after a COVID vaccine
For many patients, prescribing phentermine and topiramate separately provides the same therapeutic benefit at a fraction of the cost
Clients report visible improvements in skin tone and radiance after consistent sessions
Aminoguanidine reacts with dicarbonyls to form 3-amino-1,2,4-triazines